[Establishment of primary liver cancer model in mice].

Jin-Jin Wang, Xue-Ying Li, Jin-Ke Yi, Bei-Ling Zhao, Hui-Min Huang, Ying Wei
{"title":"[Establishment of primary liver cancer model in mice].","authors":"Jin-Jin Wang,&nbsp;Xue-Ying Li,&nbsp;Jin-Ke Yi,&nbsp;Bei-Ling Zhao,&nbsp;Hui-Min Huang,&nbsp;Ying Wei","doi":"10.12047/j.cjap.6367.2022.149","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> Three modeling methods were used to establish a mouse primary liver cancer model, and compared them to find a more optimal modeling method. <b>Methods:</b> Forty 15-day-old C3H/HeN male mice were randomly divided into groups I-IV, 10 mice in each group. Group Ⅰ were not treated; Group Ⅱ were intraperitoneally injected with 25 mg/kg diethylnitrosamine (DEN) once; Group Ⅲ were intraperitoneally injected with 100 mg/kg DEN once; Group Ⅳ were intraperitoneally injected with 25 mg/kg DEN once and followed by another intraperitoneal injection of 100 mg/kg DEN at 42 days of age. The mortality of mice in each group was analyzed. At the 18th week of modeling, blood was collected from eyeballs after anesthesia, and liver was taken from abdominal cavity after neck was broken. The appearance of liver, the number of cancer nodules and the incidence of liver tumor were observed. The histopathological changes of liver were observed by HE staining. The serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were detected. <b>Results:</b> At the 18th week of modeling, compared with the group I, serum levels of ALT and AST in groups II-IV were increased significantly (<i>P</i><0.05); The number of cancer nodules and the incidence of tumors in the surviving mice of groups III and IV were also increased significantly (<i>P</i><0.05). At the 18th week of modeling, no mice died in both groups I and II, and the incidence of liver cancer was 0%; The incidence of liver cancer in surviving mice in both groups III and IV was 100%, but the mortality rate of mice in group III was as high as 50%, and that in group IV was only 20%. <b>Conclusion:</b> C3H/HeN male mice can successfully establish a mouse liver cancer model by intraperitoneal injection of 25 mg/kg of DEN once at the age of 15 days and another intraperitoneal injection of 100 mg/kg of DEN once at the age of 42 days with short cycle and low mortality, which is an ideal method to establish a primary liver cancer model.</p>","PeriodicalId":23985,"journal":{"name":"Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology","volume":"38 6","pages":"820-823"},"PeriodicalIF":0.0000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12047/j.cjap.6367.2022.149","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Three modeling methods were used to establish a mouse primary liver cancer model, and compared them to find a more optimal modeling method. Methods: Forty 15-day-old C3H/HeN male mice were randomly divided into groups I-IV, 10 mice in each group. Group Ⅰ were not treated; Group Ⅱ were intraperitoneally injected with 25 mg/kg diethylnitrosamine (DEN) once; Group Ⅲ were intraperitoneally injected with 100 mg/kg DEN once; Group Ⅳ were intraperitoneally injected with 25 mg/kg DEN once and followed by another intraperitoneal injection of 100 mg/kg DEN at 42 days of age. The mortality of mice in each group was analyzed. At the 18th week of modeling, blood was collected from eyeballs after anesthesia, and liver was taken from abdominal cavity after neck was broken. The appearance of liver, the number of cancer nodules and the incidence of liver tumor were observed. The histopathological changes of liver were observed by HE staining. The serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were detected. Results: At the 18th week of modeling, compared with the group I, serum levels of ALT and AST in groups II-IV were increased significantly (P<0.05); The number of cancer nodules and the incidence of tumors in the surviving mice of groups III and IV were also increased significantly (P<0.05). At the 18th week of modeling, no mice died in both groups I and II, and the incidence of liver cancer was 0%; The incidence of liver cancer in surviving mice in both groups III and IV was 100%, but the mortality rate of mice in group III was as high as 50%, and that in group IV was only 20%. Conclusion: C3H/HeN male mice can successfully establish a mouse liver cancer model by intraperitoneal injection of 25 mg/kg of DEN once at the age of 15 days and another intraperitoneal injection of 100 mg/kg of DEN once at the age of 42 days with short cycle and low mortality, which is an ideal method to establish a primary liver cancer model.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
小鼠原发性肝癌模型的建立
目的:采用三种建模方法建立小鼠原发性肝癌模型,并对其进行比较,寻找更优的建模方法。方法:选取15日龄C3H/HeN雄性小鼠40只,随机分为ⅰ~ⅳ组,每组10只。Ⅰ组未处理;Ⅱ组腹腔注射25 mg/kg二乙基亚硝胺(DEN) 1次;Ⅲ组腹腔注射100 mg/kg DEN 1次;Ⅳ组在42日龄时腹腔注射一次25 mg/kg的DEN,随后再次腹腔注射100 mg/kg的DEN。分析各组小鼠的死亡率。造模第18周,麻醉后眼球采血,断颈后腹腔取肝。观察肝脏形态、肿瘤结节数及肝肿瘤发生率。HE染色观察肝组织病理变化。检测血清谷丙转氨酶(ALT)和天冬氨酸转氨酶(AST)水平。结果:造模第18周,与ⅰ组比较,ⅱ~ⅳ组大鼠血清ALT、AST水平显著升高(P<0.05);III组和IV组存活小鼠的癌结节数和肿瘤发生率均显著升高(P<0.05)。造模第18周,ⅰ组和ⅱ组均无小鼠死亡,肝癌发生率为0%;III组和IV组存活小鼠肝癌的发生率均为100%,但III组小鼠死亡率高达50%,IV组仅为20%。结论:C3H/HeN雄性小鼠15日龄腹腔注射一次DEN 25 mg/kg, 42日龄腹腔注射一次DEN 100 mg/kg,可成功建立小鼠肝癌模型,周期短,死亡率低,是建立原发性肝癌模型的理想方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.70
自引率
0.00%
发文量
53
期刊最新文献
Innovations in Drug Delivery Systems for Biologics: Enhancing Stability and Targeted Delivery for Next-Generation Therapeutics. Harnessing Pharmacogenomics for Personalized Medicine: Tailoring Drug Therapy to Genetic Profiles. Breakthrough Biomarkers in Lung Cancer: Pioneering Early Detection and Precision Treatment Strategies. Exploring Computational Advancements in ADME: Essential Insights for Drug Disposition. Oncogenetics: Unraveling the Genetic Underpinnings of Cancer for Improved Immunotherapeutic Outcomes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1